| human | Q5 |
| P496 | ORCID iD | 0000-0003-2678-1311 |
| P734 | family name | Yates | Q11927467 |
| P735 | given name | Nicole | Q14753732 |
| Nicole | Q14753732 | ||
| P106 | occupation | researcher | Q1650915 |
| Q96608755 | 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates |
| Q90555329 | Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk |
| Q95649524 | Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials |
| Q92538619 | Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway |
| Q36559838 | Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion |
| Q36753653 | Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women |
| Q49762357 | Computational analysis of antibody dynamics identifies recent HIV-1 infection |
| Q90730263 | Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC" |
| Q38793711 | Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques |
| Q36844746 | Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. |
| Q37087506 | Dose-dependent lymphocyte apoptosis following respiratory infection with Vaccinia virus |
| Q35363127 | Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection |
| Q39044405 | Epigallocatechin-3-gallate prevents autoimmune-associated down- regulation of p21 in salivary gland cells through a p53-independent pathway |
| Q56989087 | Erratum: Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel |
| Q92204630 | Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity |
| Q47547483 | HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees |
| Q89602201 | HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens |
| Q41918753 | HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine |
| Q42270590 | HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages |
| Q36874604 | HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. |
| Q35192641 | HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies |
| Q40339467 | HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci |
| Q37013490 | HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition |
| Q35914311 | Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates |
| Q40659603 | Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers |
| Q90167589 | Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa |
| Q29617377 | Immune-correlates analysis of an HIV-1 vaccine efficacy trial |
| Q50043326 | Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates |
| Q37252966 | Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization |
| Q35055183 | Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses |
| Q36978671 | Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees |
| Q34848486 | Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia |
| Q89777595 | Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs |
| Q46985274 | Lack of IgA envelope-reactive antibody producing cells in terminal ileum in early and chronic HIV-1 infection |
| Q93061613 | Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans |
| Q36184762 | Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission |
| Q36886845 | Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection |
| Q46990959 | Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial |
| Q37510242 | Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection |
| Q96693072 | Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial |
| Q92606962 | Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q36736400 | Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens |
| Q59351003 | Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost |
| Q46647938 | Proceedings of the Frontiers of Retrovirology Conference 2016. |
| Q30620607 | Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform |
| Q62487341 | Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1 |
| Q92288781 | Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector |
| Q59351008 | Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC |
| Q35058698 | Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women |
| Q59351843 | Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals |
| Q89857234 | Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines |
| Q92498017 | Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study |
| Q38757011 | Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses |
| Q35989484 | Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques |
| Q37469197 | Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques |
| Q115613293 | Vaccination induces HIV broadly neutralizing antibody precursors in humans |
| Q33977866 | Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination |
| Q34402934 | Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection |
| Q35774599 | Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation |
Search more.